Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

BioCryst Pharmaceuticals Inc

Healthcare US BCRX

8.25USD
-0.09(1.08%)

Last update at 2026-06-03T20:18:00Z

Day Range

8.068.47
LowHigh

52 Week Range

6.0011.31
LowHigh

Fundamentals

  • Previous Close 8.34
  • Market Cap2304.86M
  • Volume4228235
  • P/E Ratio7.59
  • Dividend Yield-%
  • EBITDA350.79M
  • Revenue TTM874.84M
  • Revenue Per Share TTM4.17
  • Gross Profit TTM 691.68M
  • Diluted EPS TTM1.21

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 267.39M -86.95400M -226.22900M -244.38400M -181.80900M
Minority interest - - - - -
Net income 263.86M -88.88100M -226.53900M -247.11700M -184.06200M
Selling general administrative 348.65M 252.50M 199.14M 159.37M 118.82M
Selling and marketing expenses - 13.57M 14.40M - -
Gross profit 855.76M 438.23M 326.75M 264.23M 149.91M
Reconciled depreciation 1.39M 1.25M 1.63M 1.44M 0.78M
Ebit 346.26M 11.56M -117.99000M -148.43500M -177.72000M
Ebitda 347.65M 12.81M -116.33500M -143.30800M -177.65800M
Depreciation and amortization 1.39M 1.25M 1.66M 5.13M 0.06M
Non operating income net other - - - - 55.14M
Operating income 340.99M -2.54300M -103.70900M -148.43500M -177.72000M
Other operating expenses 533.85M 453.25M 435.12M 419.26M 334.89M
Interest expense 78.87M 98.52M 108.24M 99.09M 59.29M
Tax provision 3.53M 1.93M 1.82M 2.73M 2.25M
Interest income 10.67M 14.75M 14.02M 5.13M 0.06M
Net interest income -68.20400M -83.77000M -96.09800M -93.96500M -59.23200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.53M 1.93M 0.31M 2.73M 2.25M
Total revenue 874.84M 450.71M 331.41M 270.83M 157.17M
Total operating expenses 514.77M 440.77M 430.46M 412.67M 327.63M
Cost of revenue 19.07M 12.48M 4.66M 6.59M 7.26M
Total other income expense net -73.59800M -84.41100M -122.52000M -95.94900M -4.08900M
Discontinued operations - - - - -
Net income from continuing ops 263.86M -88.88100M -236.34900M -247.11700M -184.06200M
Net income applicable to common shares - - - -247.11600M -184.06200M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 514.16M 490.42M 516.96M 550.00M 588.15M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 17.38M 13.75M 19.54M 12.59M 9.99M
Total liab 633.31M 966.35M 972.49M 844.60M 695.14M
Total stockholder equity -119.15300M -475.93400M -455.52800M -1454.62100M -1207.50400M
Deferred long term liab - - - - -
Other current liab 140.16M 113.29M 102.88M 87.56M 72.67M
Common stock 2.13M 2.08M 2.06M 1.88M 1.84M
Capital stock 2.13M 2.08M 2.06M 1.88M 1.84M
Retained earnings -1506.17900M -1770.04000M -1681.15900M -1454.62100M -1207.50400M
Other liab - - - - -
Good will - - - - -
Other assets - - - 550.00M 588.15M
Cash 89.74M 104.92M 112.45M 304.77M 504.39M
Cash and equivalents - - - - -
Total current liabilities 196.07M 160.38M 149.99M 105.51M 103.72M
Current deferred revenue - - - 1.22M 1.42M
Net debt 387.59M 736.50M 736.27M 436.69M 88.85M
Short term debt 40.08M 35.45M 26.21M 2.37M 1.82M
Short long term debt - - - - -
Short long term debt total 477.33M 841.42M 848.71M 741.45M 593.24M
Other stockholder equity 1384.86M 1291.10M 1222.24M -1.90500M -2.02000M
Property plant equipment - - - 15.42M 15.19M
Total current assets 404.35M 421.97M 495.97M 516.50M 566.14M
Long term investments 61.16M 20.32M 0.00000M 18.08M 6.83M
Net tangible assets - - - -294.59700M -147.04400M
Short term investments 185.01M 216.14M 278.34M 119.54M 3.21M
Net receivables 106.82M 79.07M 56.95M 50.60M 29.41M
Long term debt 427.23M 795.92M 811.26M 733.28M 585.46M
Inventory 5.40M 8.09M 28.68M 27.53M 15.79M
Accounts payable 15.83M 11.64M 20.89M 14.36M 27.81M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.04M 0.92M 1.34M 0.03M 0.18M
Additional paid in capital - - - - -
Common stock total equity - - - - 1.84M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -1207.50400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 29.66M 26.94M 12.03M 6.81M 6.47M
Deferred long term asset charges - - - - -
Non current assets total 109.81M 68.45M 20.99M 33.50M 22.02M
Capital lease obligations 11.64M 12.82M 13.88M 8.17M 7.78M
Long term debt total - - - - 136.08M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -5.59300M 52.59M -25.81000M -128.23800M 18.19M
Change to liabilities - - - -22.46900M 40.70M
Total cashflows from investing activities -13.69400M 52.59M -131.49800M -128.23800M 15.80M
Net borrowings -301.98900M -1.70400M 58.38M 73.07M 293.87M
Total cash from financing activities -332.44200M -5.76100M 32.48M 88.03M 359.67M
Change to operating activities - - - -2.58300M -2.98700M
Net income 263.86M -88.88100M -226.53900M -247.11600M -184.06200M
Change in cash -103.32200M -6.12400M -193.79200M -201.49500M 233.39M
Begin period cash flow 104.92M 112.45M 306.24M 507.73M 274.35M
End period cash flow 1.60M 106.32M 112.45M 306.24M 507.73M
Total cash from operating activities 329.88M -52.02000M -95.14100M -161.85000M -142.15700M
Issuance of capital stock 0.06M 0.03M 0.34M 0.00000M 50.00M
Depreciation 1.39M 1.25M 1.66M 1.44M 0.78M
Other cashflows from investing activities 0.55M -1.12400M 0.00000M - -
Dividends paid - - - - -
Change to inventory -1.63900M -4.16400M -1.45000M -12.42300M -8.76700M
Change to account receivables -36.80600M -22.69800M -6.09500M -21.47000M -23.80400M
Sale purchase of stock - - - - 65.79M
Other cashflows from financing activities -8.84700M -4.09100M -26.24000M 73.07M 309.67M
Change to netincome - - - 141.84M 33.00M
Capital expenditures 2.47M 1.12M 2.17M 1.35M 2.38M
Change receivables - - - - -20.81700M
Cash flows other operating - - - - 48.33M
Exchange rate changes - - - - 0.07M
Cash and cash equivalents changes - - - - 233.39M
Change in working capital -56.89800M -87.28200M -32.40100M -58.94500M 8.12M
Stock based compensation 85.07M 65.41M 55.62M 44.70M 34.64M
Other non cash items 121.53M 57.48M 106.53M 98.07M 54.20M
Free cash flow 327.41M -53.14400M -97.30900M -163.20100M -144.54200M

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BCRX
BioCryst Pharmaceuticals Inc		 -0.09 1.08% 8.25 7.59 114.94 2.63 56.59 2.82 7.10
ZTS
Zoetis Inc		 1.20 1.57% 77.59 40.18 30.96 10.67 17.60 11.27 26.18
MKKGY
Merck KGaA ADR		 0.58 1.91% 31.01 21.25 14.93 3.10 2.14 3.60 12.98
MKGAF
MERCK Kommanditgesellschaft auf Aktien		 - -% 153.91 21.73 14.95 3.16 2.15 3.56 12.82
GALDY
GALDERMA GROUP AG		 -0.79 1.89% 40.92 74.21 41.67 8.64 5.55 9.15 42.22

Reports Covered

Stock Research & News

View All

Profile

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. It is also developing BCX17725, a protein therapeutic for netherton syndrome which is in phase 1; Avoralstat, an ocular plasma kallikrein inhibitor for diabetic macular edema that is in Phase 1; Navenibart, a monoclonal antibody plasma kallikrein inhibitor for HAE which is in Phase 3; BCX17725, an investigational protein therapeutic KLK5 inhibitor for the treatment of netherton syndrome that is in phase 1 clinical trial; STAR-0310, a monoclonal antibody OX40 antagonist for the treatment of atopic dermatitis which is in Phase 1a trial. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., and Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

BioCryst Pharmaceuticals Inc

4505 Emperor Boulevard, Durham, NC, United States, 27703

Key Executives

Name Title Year Born
Mr. Jon P. Stonehouse CEO, Pres & Exec. Director 1961
Mr. Anthony J. Doyle Sr. VP & CFO 1980
Dr. William P. Sheridan MBBS Chief Devel. Officer 1955
Dr. Yarlagadda S. Babu Chief Discovery Officer 1953
Dr. Helen M. Thackray FAAP, M.D. Chief R&D Officer 1968
Mr. Michael L. Jones Exec. Director of Fin. & Principal Accounting Officer 1970
Ms. Alane P. Barnes Sr. VP, Chief Legal Officer & Corp. Sec. 1966
Mr. John D. Bluth Chief Communications Officer 1973
Ms. Stephanie Angelini Chief People Officer NA
Dr. Elliott T. Berger Sr. VP of Regulatory Affairs NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions